Figure 2. A priming immunization with a recombinant adenoviral vector reduces the differential antibody immunogenicity of protein-in-adjuvant vaccines.

C57BL/6 mice (n= 6 / group) were primed i.m. with 1×10¹⁰ vp of AdHu5-OVA and boosted eight weeks later i.m. with OVA formulated in adjuvant. IgG titers were measured in the serum in response to OVA protein by ELISA. (A) IgG titers measured every two weeks after AdHu5-OVA. Median responses are shown after each immunization. (B) IgG titers measured eight weeks after the AdHu5-OVA prime (pre-boost) and two weeks after the protein vaccine boost ( post-boost). Median responses are shown with range. (C) IgG titers measured two weeks after the protein vaccine. Median responses are shown with individual data points. T cell responses were assayed in the blood against the (D) pooled H-2^b CD4⁺ T cell epitopes and (E) the H-2^bCD8⁺ T cell epitope present in OVA. Median responses are shown. The dotted line indicates the threshold for responses above background in (A) – (C).